Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped down before the market opened on Friday . The stock had previously closed at $32.20, but opened at $30.50. Ascentage Pharma Group International shares last traded at $30.50, with a volume of 510 shares traded.

Analyst Ratings Changes

AAPG has been the subject of several research analyst reports. BTIG Research began coverage on shares of Ascentage Pharma Group International in a report on Monday, November 10th. They issued a “buy” rating and a $50.00 price target for the company. Piper Sandler initiated coverage on Ascentage Pharma Group International in a report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $49.00.

Ascentage Pharma Group International Price Performance

The stock’s 50 day moving average is $35.81 and its two-hundred day moving average is $35.82. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53.

Institutional Investors Weigh In On Ascentage Pharma Group International

Institutional investors have recently bought and sold shares of the company. Chevy Chase Trust Holdings LLC acquired a new position in Ascentage Pharma Group International during the 2nd quarter worth approximately $227,000. Monashee Investment Management LLC acquired a new stake in shares of Ascentage Pharma Group International in the first quarter valued at approximately $3,511,000. UBS Group AG lifted its position in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International in the second quarter worth $391,000. Finally, Citadel Advisors LLC acquired a new position in Ascentage Pharma Group International during the third quarter worth $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.